Modeling the Insulin-Like Growth Factor System in Articular Cartilage

IGF signaling is involved in cell proliferation, differentiation and apoptosis in a wide range of tissues, both normal and diseased, and so IGF-IR has been the focus of intense interest as a promising drug target. In this computational study on cartilage, we focus on two questions: (i) what are the key factors influencing IGF-IR complex formation, and (ii) how might cells regulate IGF-IR complex formation? We develop a reaction-diffusion computational model of the IGF system involving twenty three parameters. A series of parametric and sensitivity studies are used to identify the key factors influencing IGF signaling. From the model we predict the free IGF and IGF-IR complex concentrations throughout the tissue. We estimate the degradation half-lives of free IGF-I and IGFBPs in normal cartilage to be 20 and 100 mins respectively, and conclude that regulation of the IGF half-life, either directly or indirectly via extracellular matrix IGF-BP protease concentrations, are two critical factors governing the IGF-IR complex formation in the cartilage. Further we find that cellular regulation of IGF-II production, the IGF-IIR concentration and its clearance rate, all significantly influence IGF signaling. It is likely that negative feedback processes via regulation of these factors tune IGF signaling within a tissue, which may help explain the recent failures of single target drug therapies aimed at modifying IGF signaling.

[1]  Malorye Allison Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers , 2012, Nature Biotechnology.

[2]  David W. Smith,et al.  A mathematical model for targeting chemicals to tissues by exploiting complex degradation , 2011, Biology Direct.

[3]  Lihai Zhang SOLUTE TRANSPORT IN CYCLIC DEFORMED HETEROGENEOUS ARTICULAR CARTILAGE , 2011 .

[4]  P. Higgs,et al.  The advantages and disadvantages of horizontal gene transfer and the emergence of the first species , 2011, Biology Direct.

[5]  David W. Smith,et al.  On the role of diffusible binding partners in modulating the transport and concentration of proteins in tissues. , 2010, Journal of theoretical biology.

[6]  S. Schuetze,et al.  Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. , 2010, The Lancet. Oncology.

[7]  David W. Smith,et al.  The transport of Insulin-Like growth factor through cartilage , 2010 .

[8]  F. Tsai,et al.  Activation of insulin-like growth factor II receptor induces mitochondrial-dependent apoptosis through G(alpha)q and downstream calcineurin signaling in myocardial cells. , 2009, Endocrinology.

[9]  David W. Smith,et al.  Integrated model of IGF-I mediated biosynthesis in a deformed articular cartilage , 2009 .

[10]  P. Ye,et al.  Expanding the mind: insulin-like growth factor I and brain development. , 2008, Endocrinology.

[11]  David W. Smith,et al.  IGF uptake with competitive binding in articular cartilage , 2008 .

[12]  David W. Smith,et al.  A fully coupled poroelastic reactive-transport model of cartilage. , 2008, Molecular & cellular biomechanics : MCB.

[13]  C. Velloso Regulation of muscle mass by growth hormone and IGF‐I , 2008, British journal of pharmacology.

[14]  Peter Pivonka,et al.  Solute transport in cartilage undergoing cyclic deformation , 2007, Computer methods in biomechanics and biomedical engineering.

[15]  J. Frane,et al.  Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  C. Nanni,et al.  Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.

[17]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[18]  David W. Smith,et al.  The effect of cyclic deformation and solute binding on solute transport in cartilage. , 2007, Archives of biochemistry and biophysics.

[19]  E. Wilson,et al.  Control of MyoD Function during Initiation of Muscle Differentiation by an Autocrine Signaling Pathway Activated by Insulin-like Growth Factor-II* , 2006, Journal of Biological Chemistry.

[20]  L. Schäffer,et al.  Hybrid Receptors Formed by Insulin Receptor (IR) and Insulin-like Growth Factor I Receptor (IGF-IR) Have Low Insulin and High IGF-1 Affinity Irrespective of the IR Splice Variant* , 2006, Journal of Biological Chemistry.

[21]  P. Cohen,et al.  Insulin‐like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma , 2006, International journal of cancer.

[22]  A. Maroudas,et al.  A theoretical study of the distribution of insulin-like growth factor in human articular cartilage. , 2006, Journal of theoretical biology.

[23]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[24]  K. Scotlandi Targeted therapies in Ewing's sarcoma. , 2006, Advances in experimental medicine and biology.

[25]  Kimberly Forsten-Williams,et al.  Regulation of Insulin-Like Growth Factor-I (IGF-I) Delivery by IGF Binding Proteins and Receptors , 2006, Annals of Biomedical Engineering.

[26]  R. Norton,et al.  IGF-binding proteins – the pieces are falling into place , 2005, Trends in Endocrinology & Metabolism.

[27]  J. Harper,et al.  Insulin‐like growth factor ligands, receptors, and binding proteins in cancer , 2005, The Journal of pathology.

[28]  A. Seifalian,et al.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge , 2005, International Journal of Colorectal Disease.

[29]  J. Stoltz Mechanobiology: Cartilage And Chondrocyte , 2004 .

[30]  R. Norton,et al.  Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. , 2004, Journal of molecular endocrinology.

[31]  Gerard A. Ateshian,et al.  Erratum: “Modeling of Neutral Solute Transport in a Dynamically Loaded Porous Permeable Gel: Implications for Articular Cartilage Biosynthesis and Tissue Engineering,” ASME Journal of Biomechanical Engineering, 2003, 125, pp. 602–614 , 2004 .

[32]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[33]  Ilyas M. Khan,et al.  The surface of articular cartilage contains a progenitor cell population , 2004, Journal of Cell Science.

[34]  J. Tarbell,et al.  Numerical Simulation of Oxygen Mass Transfer in a Compliant Curved Tube Model of a Coronary Artery , 2004, Annals of Biomedical Engineering.

[35]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[36]  Gerard A Ateshian,et al.  Modeling of neutral solute transport in a dynamically loaded porous permeable gel: implications for articular cartilage biosynthesis and tissue engineering. , 2003, Journal of biomechanical engineering.

[37]  A. Juul Serum levels of insulin-like growth factor I and its binding proteins in health and disease. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[38]  A. Grodzinsky,et al.  Transport and binding of insulin-like growth factor I through articular cartilage. , 2003, Archives of biochemistry and biophysics.

[39]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[40]  A. Maroudas,et al.  Synthesis of insulin-like growth factor binding protein 3 in vitro in human articular cartilage cultures. , 2003, Arthritis and rheumatism.

[41]  J. Fowlkes,et al.  Insulin-like growth factor binding protein proteolysis , 1997, Trends in Endocrinology & Metabolism.

[42]  S. Mohan,et al.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. , 2002, The Journal of endocrinology.

[43]  M. Beresini,et al.  A slow release formulation of insulin as a treatment for osteoarthritis. , 2002, Osteoarthritis and cartilage.

[44]  Peter Vorwerk,et al.  Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3), IGFBP-3 N- and C-terminal fragments, and structurally related proteins mac25 and connective tissue growth factor measured using a biosensor. , 2002, Endocrinology.

[45]  Mengsu Yang,et al.  Effect of hydrogel matrix on binding kinetics of protein–protein interactions on sensor surface , 2002 .

[46]  C. Archer,et al.  The development of articular cartilage: evidence for an appositional growth mechanism , 2001, Anatomy and Embryology.

[47]  C. Osipo,et al.  Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. , 2001, Experimental cell research.

[48]  T. Nam,et al.  The Complement Component C1s Is the Protease That Accounts for Cleavage of Insulin-like Growth Factor-binding Protein-5 in Fibroblast Medium* , 2000, The Journal of Biological Chemistry.

[49]  J. Fox,et al.  ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. , 2000, Biochemical and biophysical research communications.

[50]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[51]  M. Pollak Insulin-like growth factor physiology and cancer risk. , 2000, European journal of cancer.

[52]  D. Casley,et al.  O-glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. , 2000, European journal of endocrinology.

[53]  P. Cohen,et al.  Role of insulin‐like growth factors and their binding proteins in growth control and carcinogenesis , 2000, Journal of cellular physiology.

[54]  A. Grodzinsky,et al.  The Insulin-like Growth Factors (IGFs) I and II Bind to Articular Cartilage via the IGF-binding Proteins* , 2000, The Journal of Biological Chemistry.

[55]  V. Quarmby,et al.  Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays. , 1999, Journal of pharmaceutical and biomedical analysis.

[56]  T. Chard,et al.  IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. , 1999, The Journal of endocrinology.

[57]  L. Bach Insulin-Like Growth Factor Binding Protein-6: The “Forgotten” Binding Protein? , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[58]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[59]  J. Martel-Pelletier,et al.  IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis , 1998, Inflammation Research.

[60]  E. Wilson,et al.  Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins* , 1997, The Journal of Biological Chemistry.

[61]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[62]  M. Polansky,et al.  Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. , 1997, The Journal of clinical investigation.

[63]  J. Pelletier,et al.  IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. , 1996, Osteoarthritis and cartilage.

[64]  S. Nagalla,et al.  Synthesis and Characterization of Insulin-like Growth Factor-binding Protein (IGFBP)-7 , 1996, The Journal of Biological Chemistry.

[65]  D. Le Roith,et al.  Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? , 1996, Cytokine & growth factor reviews.

[66]  R. Gill,et al.  Biosensor Measurement of the Binding of Insulin-like Growth Factors I and II and Their Analogues to the Insulin-like Growth Factor-binding Protein-3* , 1996, The Journal of Biological Chemistry.

[67]  M. Flessner,et al.  Small-solute transport across specific peritoneal tissue surfaces in the rat. , 1996, Journal of the American Society of Nephrology : JASN.

[68]  R. Schneiderman,et al.  Concentration and size distribution of insulin-like growth factor-I in human normal and osteoarthritic synovial fluid and cartilage. , 1995, Archives of biochemistry and biophysics.

[69]  J. van Marle,et al.  Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis. , 1995, Annals of the rheumatic diseases.

[70]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[71]  J. Pelletier,et al.  Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1-binding proteins. , 1994, Arthritis and rheumatism.

[72]  P. Franchimont,et al.  Tumor IGF‐II content in a patient with a colon adenocarcinoma correlates with abnormal expression of the gene , 1991, International journal of cancer.

[73]  E. Froesch,et al.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. , 1989, Acta endocrinologica.

[74]  D. Schalch,et al.  Interaction of insulin-like growth factor II with rat chondrocytes: receptor binding, internalization, and degradation. , 1987, Endocrinology.

[75]  Lee A. Segel,et al.  Modeling Dynamic Phenomena in Molecular and Cellular Biology , 1984 .

[76]  M A Freeman,et al.  The composition of normal and osteoarthritic articular cartilage from human knee joints. With special reference to unicompartmental replacement and osteotomy of the knee. , 1984, The Journal of bone and joint surgery. American volume.